ONE CASE OF TOXIC EPIDERMAL NECROLYSIS AFTER TREATMENT WITH BELIMUMAB IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

ONE CASE OF TOXIC EPIDERMAL NECROLYSIS AFTER TREATMENT WITH BELIMUMAB IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Belimumab is a human immunoglobulin G1-lambda-1 (IgG1-λ) monoclonal antibody that targets the soluble BLyS human protein, also known as B-cell activating factor (BAFF) approved for the treatment of systemic lupus erythematosus (SLE). Serious and sometimes fatal infections have been reported in patie...

Full description

Bibliographic Details
Main Authors: Madalina Duna, Dinu Valentin Balanescu, Cristina Iosif, Narcis Copca, Denisa Predeteanu, Ruxandra Ionescu
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2019-09-01
Series:Romanian Journal of Rheumatology
Subjects:
systemic lupus erythematosus
autoimmune disease
toxic epidermal necrolysis
belimumab
Online Access:https://revistemedicale.amaltea.ro/Romanian_Journal_of_RHEUMATOLOGY/Revista_Romana_de_REUMATOLOGIE-2019-Nr.3/RJR_2019_3_Art-05.pdf

Internet

https://revistemedicale.amaltea.ro/Romanian_Journal_of_RHEUMATOLOGY/Revista_Romana_de_REUMATOLOGIE-2019-Nr.3/RJR_2019_3_Art-05.pdf

Similar Items